Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive CancersGlobeNewsWire • 01/09/23
Context Therapeutics has 39.4M cash runway to advance pipeline programs; data update from OATH Phase 2 trial likely in mid-2023Proactive Investors • 01/04/23
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline MilestonesGlobeNewsWire • 01/04/23
Context Therapeutics reports encouraging preliminary Phase 2 data for ONA-XR in metastatic breast cancerProactive Investors • 12/08/22
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast CancerGlobeNewsWire • 12/08/22
Context Therapeutics finds lead clinical development candidate for cancer treatment in CTIM-76Proactive Investors • 11/29/22
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid TumorsGlobeNewsWire • 11/29/22
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer SymposiumGlobeNewsWire • 11/21/22
Context Therapeutics ends 3Q with a substantial $39M cash runway to advance pipeline programsProactive Investors • 11/10/22
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial ResultsGlobeNewsWire • 11/09/22
Context Therapeutics CEO charts path for fiscal stability into 2024, tightens focus on Phase 1b ELONA breast cancer trialProactive Investors • 09/27/22
Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/06/22
Context Therapeutics ends 2Q with strong $42.9M cash runway to advance pipeline programsProactive Investors • 08/11/22
Context Therapeutics® Reports Second Quarter 2022 Operating and Financial ResultsGlobeNewsWire • 08/11/22
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant CombinationPRNewsWire • 08/02/22
Context Therapeutics collaborates with Menarini Group to evaluate ONA-XR and elacestrant combinationProactive Investors • 08/02/22
Context Therapeutics ends 1Q with $45.7M as it gears up for 'pivotal' 2022Proactive Investors • 05/11/22
Context Therapeutics® Reports First Quarter 2022 Operating and Financial ResultsGlobeNewsWire • 05/11/22
Context Therapeutics announces poster presentation at upcoming 2022 ASCO annual meetingProactive Investors • 05/05/22
Context Therapeutics reveals “encouraging” preclinical data from two cancer-treating pipeline programsProactive Investors • 04/11/22
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 04/11/22